Rallybio Co. (NASDAQ:RLYB – Get Rating) insider Jonathan I. Lieber acquired 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The stock was bought at an average cost of $5.21 per share, with a total value of $26,050.00. Following the completion of the transaction, the insider now directly owns 5,000 shares in the company, valued at $26,050. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.
Rallybio Price Performance
RLYB opened at $4.59 on Friday. Rallybio Co. has a 12-month low of $4.54 and a 12-month high of $15.89. The firm has a 50 day moving average of $6.79 and a two-hundred day moving average of $8.02.
Rallybio (NASDAQ:RLYB – Get Rating) last posted its quarterly earnings results on Monday, March 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.14. As a group, sell-side analysts predict that Rallybio Co. will post -2.09 earnings per share for the current year.
Analyst Upgrades and Downgrades
Hedge Funds Weigh In On Rallybio
Several institutional investors have recently made changes to their positions in the company. State of Tennessee Treasury Department purchased a new position in shares of Rallybio during the 4th quarter valued at approximately $109,000. Utah Retirement Systems purchased a new position in shares of Rallybio during the 4th quarter valued at approximately $87,000. Squarepoint Ops LLC purchased a new position in shares of Rallybio during the 4th quarter valued at approximately $87,000. Laurion Capital Management LP increased its holdings in shares of Rallybio by 94.8% during the 4th quarter. Laurion Capital Management LP now owns 783,291 shares of the company’s stock valued at $5,146,000 after purchasing an additional 381,291 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Rallybio by 15.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 46,477 shares of the company’s stock valued at $305,000 after purchasing an additional 6,230 shares in the last quarter. 91.97% of the stock is owned by hedge funds and other institutional investors.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).
- Get a free copy of the StockNews.com research report on Rallybio (RLYB)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.